Evaluation of Galcanezumab for the Prevention of Episodic Migraine

Migraine is a debilitating condition marked by severe headache attacks. Current treatments often reduce migraine frequency but can cause adverse effects. This study assessed galcanezumab's efficacy compared to placebo for preventing episodic migraine. The EVOLVE-1 trial was conducted from January to March 2017, involving 1671 patients. Of these, 858 patients met entry criteria and received treatment. Participants were aged 18 to 65, with a history of migraines. They received monthly doses of galcanezumab (120 mg or 240 mg) or placebo for six months. Results showed that both galcanezumab doses significantly reduced monthly migraine days by 4.7 days for 120 mg and 4.6 days for 240 mg. The study also noted a high treatment completion rate of 81.9%. Adverse events were low, with less than 5% discontinuation due to side effects. Galcanezumab proved effective and well-tolerated for migraine prevention. Clinical relevance: This study indicates that galcanezumab effectively reduces monthly migraine days with a favorable safety profile.